Close

Form 6-K/A GLAXOSMITHKLINE PLC For: Jan 15

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/18/2024

1. JBHT
2. UAL
3. TSLA
4. SAGE
5. TRV
6. ASML
7. SLG
8. PLD
9. OMC
10. IBKR


January 15, 2015 1:34 PM EST

FORM 6-K/A
�
�
SECURITIES AND EXCHANGE COMMISSION(
Washington D.C. 20549
�
�
Report of Foreign Issuer
�
�
Pursuant to Rule 13a-16 or 15d-16 of(
the Securities Exchange Act of 1934
�
�
�
For period ending�January 2015
�
GlaxoSmithKline plc
(Name of registrant)(

�
�
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)(

�
�
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F(

�
�
Form 20-F x��� �Form 40-F(
�
--(
�
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.(

�
�
Yes����� No x
--

�
This announcement replaces the original announcement released on 5 January 2015.

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the 'Company').

On 31 December 2014, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2014; calculated using an average price of �13.84 per Ordinary Share and $42.91 per ADS:
�
Non-Executive Director
Ordinary Shares
No. of ADSs
Sir Christopher Gent
6,385.452
 �
Prof Sir Roy Anderson
1,003.260
 �
Dr Stephanie Burns
 �
886.521
Stacey Cartwright
256.043
 �
Lynn Elsenhans
 �
308.422
Judy Lewent
 �
208.857
Sir Deryck Maughan
 �
2,255.597
Dr Daniel Podolsky
 �
1,613.970
Tom de Swaan
1,389.497
 �
Jing Ulrich
 �
98.139
Hans Wijers
76.661
 �

The Company and the Non-Executive Directors were informed of these allocations on 5 January 2015.

This notification relates to transactions notified in accordance with�Disclosure and Transparency Rule 3.1.4R(1)(a).


V A Whyte
Company Secretary
�
15 January 2015

�
SIGNATURES
�
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.(


�
�
GlaxoSmithKline plc
(Registrant)(

Date:�January�15,�2015�
�
�
By:�VICTORIA WHYTE
----------------------
�
�
Victoria�Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings